UCB shares surge 16% after Bimzelx outperforms competitor in HS trials
PositiveFinancial Markets

UCB's shares have jumped 16% following the impressive performance of their drug Bimzelx in head-to-head trials against a competitor. This surge reflects investor confidence in UCB's innovative approach to treating conditions related to HS, highlighting the potential for Bimzelx to capture significant market share. The positive trial results not only bolster UCB's position in the pharmaceutical industry but also promise better treatment options for patients.
— Curated by the World Pulse Now AI Editorial System